The Anti-Diabetic PPARγ Agonist Pioglitazone Inhibits Cell Proliferation and Induces Metabolic Reprogramming in Prostate Cancer
Summary by Stemwell Science News
3 Articles
3 Articles
All
Left
Center
Right
The Anti-Diabetic PPARγ Agonist Pioglitazone Inhibits Cell Proliferation and Induces Metabolic Reprogramming in Prostate Cancer
The authors suggested that Pioglitazone reduces prostate cancer (PCa) cell proliferation and induces metabolic and epithelial changes, highlighting the potential of repurposing metabolic drugs for PCa therapy. [Molecular Cancer] Full Article
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage